ATE366238T1 - Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 - Google Patents

Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3

Info

Publication number
ATE366238T1
ATE366238T1 AT01928117T AT01928117T ATE366238T1 AT E366238 T1 ATE366238 T1 AT E366238T1 AT 01928117 T AT01928117 T AT 01928117T AT 01928117 T AT01928117 T AT 01928117T AT E366238 T1 ATE366238 T1 AT E366238T1
Authority
AT
Austria
Prior art keywords
glycogen synthase
synthase kinase
disease
heterocyclic inhibitors
gsk
Prior art date
Application number
AT01928117T
Other languages
English (en)
Inventor
Gil Ana Martinez
Morera Ana Castro
Martin Maria Concepcion Perez
Mercedes Alonso Cascon
Isabel Diaz
Munoz Francisco Jose Moreno
Jurado Wandosell
Original Assignee
Consejo Superior Investigacion
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200001185A external-priority patent/ES2166328B1/es
Application filed by Consejo Superior Investigacion, Univ Madrid Autonoma filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE366238T1 publication Critical patent/ATE366238T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01928117T 2000-05-11 2001-05-11 Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 ATE366238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200001185A ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en) 2000-05-11 2000-12-12 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
ATE366238T1 true ATE366238T1 (de) 2007-07-15

Family

ID=26156184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928117T ATE366238T1 (de) 2000-05-11 2001-05-11 Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3

Country Status (19)

Country Link
US (3) US6872737B2 (de)
EP (1) EP1286964B1 (de)
KR (1) KR100812407B1 (de)
CN (1) CN100358867C (de)
AT (1) ATE366238T1 (de)
AU (1) AU783615B2 (de)
BR (1) BR0110734A (de)
CA (1) CA2408747C (de)
CY (1) CY1106826T1 (de)
CZ (1) CZ296087B6 (de)
DE (1) DE60129222T2 (de)
DK (1) DK1286964T3 (de)
ES (1) ES2288948T3 (de)
HU (1) HUP0302002A3 (de)
IL (1) IL152721A0 (de)
MX (1) MXPA02011079A (de)
PL (1) PL209780B1 (de)
RU (1) RU2294931C2 (de)
WO (1) WO2001085685A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE366238T1 (de) * 2000-05-11 2007-07-15 Consejo Superior Investigacion Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
WO2003018011A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
WO2003018554A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
CN1741821B (zh) * 2002-10-29 2011-08-10 恩根尼公司 用于癌症治疗的组合物
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
GB0327908D0 (en) * 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
EP1574499A1 (de) * 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum DNA-Methylerungshemmer in Tumorzellen
EP1586318A1 (de) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinone als GSK3-Inhibitoren
US8771754B2 (en) * 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
EP1838685A4 (de) * 2005-01-10 2010-01-27 Astrazeneca Ab Derivate von isothiazol-3-(2h)-thion-1,1-dioxiden als liver-x-rezeptormodulatoren
BRPI0606388A2 (pt) * 2005-01-10 2009-11-17 Astrazeneca Ab composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
DK1846406T5 (da) 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
US9180118B2 (en) 2006-07-18 2015-11-10 University Of Rochester Thiadiazolidinone derivatives
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2089017A2 (de) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Glycolyse-/glycogenolyse-hemmer für schmerzbehandlung
US8513292B2 (en) 2007-06-22 2013-08-20 Arqule, Inc. Compositions and methods for the treatment of cancer
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
BRPI0813355A2 (pt) 2007-06-22 2014-12-30 Arqule Inc Compostos de quinazolinona e métodos de uso dos mesmos
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
ES2927660T3 (es) * 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
HRP20160353T1 (hr) * 2009-07-08 2016-05-06 Baltic Bio Ab Derivati 1,2,4-tiazolidin-3-ona i njihova uporaba u liječenju raka
ITNA20090047A1 (it) * 2009-07-16 2011-01-17 Adele Bolognese Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
CA2785410A1 (en) * 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US11068954B2 (en) 2015-11-20 2021-07-20 Voicemonk Inc System for virtual agents to help customers and businesses
CN103237793B (zh) 2010-12-01 2015-06-10 日产化学工业株式会社 具有多发性骨髓瘤的治疗效果的吡唑化合物
US8865750B2 (en) * 2011-04-28 2014-10-21 The Regents Of The University Of Michigan Small molecule inhibitors of RGS proteins
EP2527323A1 (de) 2011-05-24 2012-11-28 Noscira, S.A. Harnstoffcarbonyldisulfidderivate und deren therapeutische Verwendungen
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
SI2838888T1 (sl) 2012-02-24 2017-09-29 Asd Therapeutics Partners Llc Tiadiazolidindioni kot gsk-3 inhibitorji
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
EP2974726A4 (de) * 2013-03-14 2017-01-04 Tiacen Ltd Mittel zur prophylaxe und/oder behandlung von neoplastischen krankheiten
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
RU2522449C1 (ru) * 2013-03-14 2014-07-10 Общество с ограниченной ответственностью "Лечебное питание" Средство, обладающее антипролиферативным и антиметастатическим действием, для лечения опухолевых заболеваний
WO2015017549A1 (en) * 2013-07-30 2015-02-05 University Of South Florida (A Florida Non-Profit Corporation) Treating an atypical protein kinase c enzyme abnormality
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
AU2015311816B2 (en) 2014-09-03 2019-04-04 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US9540462B2 (en) 2014-12-05 2017-01-10 Massachusetts Institute Of Technology Catechol-rich polymers from N-substituted maleimides
EA032630B9 (ru) 2015-03-17 2019-11-27 Regeneron Pharma Реагенты аминокислотного ацилирования и способы их использования
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
RU2761429C2 (ru) * 2018-06-13 2021-12-08 Общество с ограниченной ответственностью "Тиацен" Средство, обладающее противоопухолевым действием, для лечения онкологических заболеваний
EP3837351A1 (de) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von haarzellen durch herunterregulierung von foxo
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN110698380B (zh) * 2019-10-24 2021-01-15 华东理工大学 一种内酰胺衍生物及其制备方法与应用
KR20230147076A (ko) * 2021-02-11 2023-10-20 벤카 리서치, 인크. 부정맥유발성 심근병증 치료를 위한 조성물 및 방법
CA3219537A1 (en) 2021-05-21 2022-11-24 Michael Snape Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (de) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinone zur verwendung in der behandlung von gliedergürtel-muskeldystrophie
CN116675653B (zh) * 2022-07-22 2024-10-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863803A (en) * 1957-05-13 1958-12-09 Stauffer Chemical Co Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en) 1964-11-16 1967-01-31 Olin Mathieson S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de) 1966-05-23 1970-11-12 Bayer Ag Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en) * 1967-02-10 1975-08-19 Velsicol Chemical Corp New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en) 1968-05-28 1970-10-13 Velsicol Chemical Corp Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de) 1971-03-02 1972-09-07 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Substituierte Thiadiazolidindione
US4183816A (en) * 1978-11-01 1980-01-15 Olin Corporation Use of 2,4-di(lower alkyl)-1,2,4-thiadiazolidin-3,5-diones as additives for functional fluids
JPS58216177A (ja) 1982-06-10 1983-12-15 Sumitomo Chem Co Ltd フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
AU1339895A (en) * 1993-12-23 1995-07-10 Eli Lilly And Company Protein kinase c inhibitors
JP3714685B2 (ja) * 1994-05-18 2005-11-09 第一サントリーファーマ株式会社 ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体
DE4420522A1 (de) * 1994-06-13 1995-12-14 Bayer Ag Bakterizide Thiadiazolidinone
HK1038564A1 (zh) * 1998-10-08 2002-03-22 Smithkline Beecham Plc 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
ATE366238T1 (de) * 2000-05-11 2007-07-15 Consejo Superior Investigacion Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
GB0012056D0 (en) * 2000-05-18 2000-07-12 Consejo Superior Investigacion Model for neurodegenerative disease
EP1586318A1 (de) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinone als GSK3-Inhibitoren

Also Published As

Publication number Publication date
CA2408747C (en) 2011-04-05
US7666885B2 (en) 2010-02-23
US20030195238A1 (en) 2003-10-16
ES2288948T3 (es) 2008-02-01
US20080033012A1 (en) 2008-02-07
DE60129222D1 (de) 2007-08-16
CA2408747A1 (en) 2001-11-15
WO2001085685A1 (en) 2001-11-15
AU783615B2 (en) 2005-11-17
KR20030025919A (ko) 2003-03-29
HUP0302002A3 (en) 2007-02-28
US20050014803A1 (en) 2005-01-20
US7781463B2 (en) 2010-08-24
RU2294931C2 (ru) 2007-03-10
DK1286964T3 (da) 2007-10-01
PL359671A1 (en) 2004-09-06
AU5498101A (en) 2001-11-20
MXPA02011079A (es) 2004-08-19
BR0110734A (pt) 2003-02-04
CN1568310A (zh) 2005-01-19
CN100358867C (zh) 2008-01-02
EP1286964A1 (de) 2003-03-05
CZ20023692A3 (cs) 2003-06-18
PL209780B1 (pl) 2011-10-31
KR100812407B1 (ko) 2008-03-11
CY1106826T1 (el) 2012-05-23
HUP0302002A2 (hu) 2003-09-29
CZ296087B6 (cs) 2006-01-11
EP1286964B1 (de) 2007-07-04
DE60129222T2 (de) 2008-03-06
US6872737B2 (en) 2005-03-29
IL152721A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
DE60129222D1 (de) Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
DE60215814D1 (de) Vinylphenyl-derivate als glk-aktivatoren
MXPA03012004A (es) Derivados de aminonicotinato como moduladores de glucocinasa (glk).
ATE334973T1 (de) Chinazolinverbindungen
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
BR0116411A (pt) Compostos de pirazol úteis como inibidores de proteìna cinase
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
MY146279A (en) Compounds affecting glucokinase
ATE466581T1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
GB0112348D0 (en) Compounds
SI1648874T1 (sl) Piperazinski derivati in njihova uporaba kot terapevtska sredstva
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
DE60229046D1 (de) Chinazolin derivate
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE279410T1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
ATE260655T1 (de) Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen